Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 70.7%

Neg 0% Neu 0% Pos 70.7%

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.